Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BS3054 > 14th and 17th Oct > Flashcards

14th and 17th Oct Flashcards

1
Q

Outline del Castillo and Katz (1957) model of drug action at GPCRs

A

A+R AR AR*

For GPCRs: A+R AR+G ARG –> Response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Outline de Lean’s (1980) Ternary complex model

A

It is cyclic

A+R AR+G ARG A+RG A+R….

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Does GTP binding affect the affinity of the receptor?

A

Yes the agonists GTP presence increases the binding affinity of the receptor with the -GTP curve being slightly sigmoidal indicating heterogeneous binding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Outline the Extended Tertiary Complex Model by Samama et al., 1993

A

AR AR- AR-G R-G R- R AR…

This takes into account agonist independent R-R* conformational change

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the name of Weiss’ model in 1996?

A

The Cubic ternary complex model

This is the most encompassing model

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Does ligand binding induce receptor conformational change?

A

No, the receptor is a dynamic structure therefore will naturally oscillate between R and R* states. Ligand binding stabilises the R* state.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the ratio of R to R* upon full agonist binding?

A

R*»R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the ratio of R to R* upon partial agonist binding?

A

R*>R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the ratio of R to R* upon antagonist binding?

A

R*=R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the ratio of R to R* upon inverse agonist binding?

A

R*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is a CAM GPCR?

A

A constitutively active mutant GPCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the key regions of a GPCR that give rise to CAMs?

A

D/ERY sequence mutations
Membrane proximal regions of the i3 loop
TM6/e4 interface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What disease is caused by a CAM TSH receptor?

A

Hyperthyroidism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is caused by a CAM Luteinising Hormone Receptor?

A

Male precocious puberty - which drives puberty in men as young as 3 yo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What disease is caused by a CAM Rhodopsin?

A

Retinitis pigmentosa and night blindness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What disease is caused by a CAM parathyroid hormone receptor?

A

Short-limb dwarfism

17
Q

What disease is caused by a CAM Ca2+ sensing receptor?

A

Hypocalaemia/hypercalcuria

18
Q

Do neutral antagonists and inverse agonists cause pharmacologically distinct actions?

A

In a quiescent system neutral antagonists and inverse agonists are functionally indistinguishable

In a constitutively active system neutral antagonists and inverse agonists have very different effects. Only inverse agonists will suppress constitutive activity therefore are the only likely drugs for diseases caused by CAM GPCRs

19
Q

Why is the choice between neutral antagonists and inverse agonists therapeutically important?

A

In a constitutively active system neutral antagonists will not suppress activity.

Treatment with inverse agonists can cause effects on receptor expression levels e.g. chronic treatment w/ histamine

20
Q

Can GPCRs adopt multiple conformational states?

A

Yes

21
Q

How can we observe receptor conformational change?

A

Monitor how FRET changes after agonist application

Crystallographic information on GPCR structure - allows us to look at different activity states of GPCRs e.g. Rhodopsin

22
Q

What are the differences between bound and unbound GPCR opsins structures?

A

Differences between bound and unbound:

  • In binding pocket part of the space usually occupied by the ligand is filled by Trp265
  • The cytoplasmic end of TM6 is moved outward therefore activating the receptor
  • The unbound form has two openings of the retinal binding pocket
23
Q

What is biased agonism?

A

When one ligand binding promotes one conformation and thus one molecular pathway, and another ligand binding to the same receptor promotes a different conformation and thus a different molecular pathway.

24
Q

What is the evidence for agonist-directed trafficking of receptor stimuli?

A

Berg 1998
5HT-2 receptors were targeted by a variety of ligands with a cell background
All ligands stimualted both Gi and Gq
TFMPP and Quipazine have a higher maximal response for Gq (measured through IP3 accumulation)
DOI and LSD have a higher maximal response for Gi (measured through aa release)

–> the different ligands appear to bias the output of the receptor

25
Q

Outline allosteric modulation of the GABAa receptor

A

The orthosteric site = alpha beta subunit interfaces
Activation can be modulated by benzodiazepiens binding at the interface between alpha and a gamma subunit altering the ability of GABA to gate the channel

FOR ALLOSTERIC ACTION GABA MUST BE BOUND AT THE ORTHOSTERIC SITE

Positive Allosteric Modulator (PAM) - BZD agonists enhance GABA evoked Cl- conductance at sub maximal [GABA]

Neutral Allosteric Modulator - BZD antagonists can block PAM and NAM action

Negative Allosteric Modulator (NAM) - BZD inverse agonists decrease GABA enabled Cl- conductance

26
Q

Give an example of a postive allosteric modulator for GABAa receptor

A

Diazepam

27
Q

Give an example of a neutral allosteric modulator for the GABAa receptor

A

Flumanezil

28
Q

Give an example of a negative allosteric modulator

A

sapmazenil

29
Q

What are the three different classes of allosteric binding sites?

A

Class A
Class B
Class C

30
Q

What are the three main effects that allosteric modulation can have

A

Altering orthosteric ligand binding affinity
Altering orthosteric ligand efficacy
Direct allosteric agonism

31
Q

What are the advantages of targeting allosteric sites when developing drugs?

A

Orthosteric binding sites are usually fairly conserved therefore specificity is difficult. Allosteric sites are much less conserved
Allosteric modulators can alter the activity of endogenous ligands without altering the pattern of stimulation therefore complex intermittent/phasic patterns of receptor stimulation can be preserved

32
Q

What is a protean agonist?

A

a protean agonist would produce an agonist
response in a quiescent receptor system (consisting of receptors the majority of
which are in the inactive state) and be an inverse agonist in a constitutively active
receptor system (one in which the receptors have been induced into the active state
with respect to G-protein coupling)

33
Q

What did flourescence lifetime spectroscopy of beta2 adrenoceptors labelled at Cys265 show?

A

Showed a Gaussian distribution for probe environments indicating continuous fluctuations in receptor conformation

34
Q

What are RAMPs?

A

Receptor activity modifying proteins

35
Q

What is homolgous desensitisation of receptors?

A

Phosphorylation of agonist occupied receptors

36
Q

What is heterologous desensitisation of receptors?

A

Phosphorylation of all GPCRs of that type

37
Q

Who introduced the concept of constitutively active receptors in 1989?

A

Costa and Herz

BS3054 (25 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions